Spesolimab Improves Quality of Life in Generalized Pustular Psoriasis (GPP) as Measured by Proportion of Patients With Dermatology Life Quality Index (DLQI) Scores of 0 or 1 and Reduction in Pain Severity Over Time: Results From the EFFISAYIL® 2 Trial. J of Skin [Internet]. 2025 Nov. 10 [cited 2026 Apr. 20];9(6):s652. Available from: https://skin.dermsquared.com/skin/article/view/3926